Philips brings AI into the procedure room to assist doctors during heart valve repair
Philips (NYSE: PHG) on November 17, 2025 introduced DeviceGuide, an AI-powered device-tracking solution on the EchoNavigator platform that assists physicians during minimally invasive mitral valve repair (M-TEER).
DeviceGuide combines live echo and X-ray to generate a real-time 3D model of the repair device, helping clinicians visualize device position and orientation inside the beating heart. It was developed with Edwards Lifesciences and will be previewed at London Valves 2025. Availability depends on local regulatory clearance and DeviceGuide is currently intended for use only with the Edwards PASCAL Ace mitral TEER device.
Philips (NYSE: PHG) il 17 novembre 2025 ha introdotto DeviceGuide, una soluzione di tracciamento dei dispositivi alimentata dall'IA sulla piattaforma EchoNavigator che assiste i medici durante la riparazione mitrale minimamente invasiva (M-TEER).
DeviceGuide combina ecografia in tempo reale e radiografia per generare un modello 3D in tempo reale del dispositivo di riparazione, aiutando i clinici a visualizzare la posizione e l'orientamento del dispositivo all'interno del cuore che batte. È stato sviluppato con Edwards Lifesciences e sarà presentato in anteprima a London Valves 2025. La disponibilità dipende dall'approvazione regolatoria locale e DeviceGuide è attualmente destinato all'uso solo con il dispositivo mitral TEER Edwards PASCAL Ace.
Philips (NYSE: PHG) el 17 de noviembre de 2025 presentó DeviceGuide, una solución de seguimiento de dispositivos impulsada por IA en la plataforma EchoNavigator que ayuda a los médicos durante la reparación mitral mínimamente invasiva (M-TEER).
DeviceGuide combina ecografía en vivo y rayos X para generar un modelo 3D en tiempo real del dispositivo de reparación, ayudando a los clínicos a visualizar la posición y la orientación del dispositivo dentro del corazón que late. Fue desarrollado con Edwards Lifesciences y se mostrará en Londres Valves 2025. La disponibilidad depende de la aprobación regulatoria local y DeviceGuide está actualmente destinado solo para su uso con el dispositivo mitral TEER Edwards PASCAL Ace.
Philips (NYSE: PHG) 는 2025년 11월 17일 EchoNavigator 플랫폼에서 DeviceGuide를 공개했습니다. 이는 AI 기반의 기기 추적 솔루션으로, 최소 침습적 승모판막 재수리(M-TEER) 중 의사를 돕습니다.
DeviceGuide는 라이브 에코와 X-레이를 결합해 재수리 기기의 실시간 3D 모델을 생성하여 맥박하는 심장 안에서 기기의 위치와 방향을 시각화하는 데 도움을 줍니다. Edwards Lifesciences와 함께 개발되었으며 London Valves 2025에서 예고될 예정입니다. 현지 규제 승인에 따라 사용 가능 여부가 달라지며 DeviceGuide는 현재 Edwards PASCAL Ace mitral TEER 기기와의 사용만 의도되어 있습니다.
Philips (NYSE: PHG) le 17 novembre 2025 a présenté DeviceGuide, une solution de suivi des dispositifs alimentée par l'IA sur la plateforme EchoNavigator qui aide les médecins lors de la réparation mitrale mini-invasive (M-TEER).
DeviceGuide combine échographie en direct et radiographie pour générer un modèle 3D en temps réel du dispositif de réparation, aidant les cliniciens à visualiser la position et l'orientation du dispositif dans le cœur qui bat. Il a été développé avec Edwards Lifesciences et sera présenté en avant-première à London Valves 2025. La disponibilité dépend de l'approbation réglementaire locale et DeviceGuide est actuellement destiné à une utilisation uniquement avec le dispositif mitral TEER Edwards PASCAL Ace.
Philips (NYSE: PHG) hat am 17. November 2025 DeviceGuide, eine KI-gesteuerte Lösung zur Verfolgung von Geräten auf der EchoNavigator-Plattform, vorgestellt, die Ärzte während der minimalinvasiven Mitralklappenreparatur (M-TEER) unterstützt.
DeviceGuide kombiniert Live-Echo und Röntgen, um ein Echtzeit-3D-Modell des Reparaturgeräts zu erzeugen und Kliniker dabei zu unterstützen, Position und Orientierung des Geräts im schlagenden Herzen zu visualisieren. Es wurde mit Edwards Lifesciences entwickelt und wird auf der London Valves 2025 erstmals vorgestellt. Die Verfügbarkeit hängt von der lokalen Zulassung ab, und DeviceGuide ist derzeit ausschließlich für die Verwendung mit dem Edwards PASCAL Ace Mitral-TEER-Gerät vorgesehen.
Philips (NYSE: PHG) في 17 نوفمبر 2025 قدمت DeviceGuide، حل تتبّع الأجهزة بالذكاء الاصطناعي على منصة EchoNavigator التي تساعد الأطباء أثناء إصلاح صِمام ميترالي بالحد الأدنى من التدخل (M-TEER).
يجمع DeviceGuide بين التصوير بالموجات فوق الصوتية الحيّ والإشعاع لإنتاج نموذج ثلاثي الأبعاد في الوقت الفعلي لجهاز الإصلاح، مما يساعد الأطباء على تصور موضع الجهاز واتجاهه داخل القلب النابض. تم تطويره مع Edwards Lifesciences وسيتم عرضه في لندن فَالفِيز 2025. تتوقف التوفر على الموافقات التنظيمية المحلية، وفي الوقت الحالي يُقصد استخدام DeviceGuide مع جهاز TEER الميترالي Edwards PASCAL Ace فقط.
- Introduced AI device-tracking for M-TEER procedures
- Real-time 3D visualization combining echo and X-ray
- Developed in collaboration with Edwards Lifesciences
- Not available for sale in all countries pending regulatory clearance
- Currently limited to Edwards PASCAL Ace device compatibility
Insights
Philips introduced DeviceGuide, an AI-enabled tracking tool to assist transcatheter mitral valve repair in real time.
DeviceGuide embeds an AI algorithm into the procedure room via the EchoNavigator platform to automatically track the Mitral TEER Therapy Device (Edwards PASCAL Ace) and fuse live echo and X-ray into a 3D device overlay. That workflow directly addresses a clear clinical pain point: coordinating multi‑modal imaging and precise device positioning during minimally invasive mitral valve repair.
The main dependencies are explicit: regulatory clearance and regional market release, and the solution is limited to the specified device and to countries where it is approved. Clinical teams retain full control; the software is described solely as an assistive visualization tool and does not perform therapy.
Key items to watch in the near term include regulatory availability by region, clinical adoption at centers previewing it at
November 17, 2025
Innovation uses AI to track and visualize tiny repair devices* through the beating heart, helping clinicians navigate in 3D with enhanced clarity and confidence**
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced DeviceGuide, an AI-powered device tracking* solution that assists physicians during one of interventional cardiology’s most technically demanding procedures: repairing leaking heart valves through a minimally invasive approach. Built on Philips’ EchoNavigator platform, this software brings AI directly into the procedure room, translating complex imaging into intuitive, real-time visual guidance that helps clinicians navigate the beating heart with greater clarity and confidence. It will be previewed at London Valves 2025 (November 16-18), one of the world’s leading meetings for structural heart specialists.
“With DeviceGuide, we’re bringing AI into the heart of the procedure room, and into the heart itself,” said Dr. Atul Gupta, Chief Medical Officer, Diagnosis & Treatment at Philips. “This is Philips’ first AI assisting physicians in real time to visualize and guide heart valve treatment devices* as they navigate the beating heart. It’s helping doctors in the moment as they are helping their patients with structural heart disease.”
Minimally invasive treatment of the mitral valve
A leaking heart valve, known as mitral valve regurgitation, is a condition in which blood leaks backward through the heart’s mitral valve. It affects more than 35 million [1] adults worldwide, leaving many short of breath, fatigued, and struggling with everyday activities like climbing stairs or walking short distances. Many also live with anxiety or fear, knowing their heart isn’t pumping efficiently. If left untreated, severe cases can lead to heart failure and other serious complications.
For patients who are too frail for open-heart surgery, minimally invasive transcatheter repair techniques such as mitral transcatheter edge-to-edge repair (M-TEER) offer a vital treatment option. During these procedures, physicians repair a leaking valve through a tiny incision in the top of the leg in the groin area, guiding long, flexible instruments through the blood veins and navigating a miniature repair device into the beating heart.
Clinicians must view and interpret both X-ray and ultrasound images on multiple screens, coordinate movements between two operators, and make precise adjustments to grasp the moving valve leaflets, position the repair device, and confirm the result in real time. The process demands accuracy, coordination, and experience from the team. This is where DeviceGuide can help with its 3D navigation support.
How AI is helping
DeviceGuide uses an AI algorithm to automatically track the tiny repair device as it moves through the beating heart, intelligently combining live echo and X-ray images. It creates a virtual 3D model of the treatment device in real time, superimposed on the live images of the beating heart. This allows clinicians to see where the device is and in which direction it is pointing, providing a clear view of the procedure and potentially enabling them to navigate the device more easily to effectively seal the leak.
“The AI software serves as an assistive tool, with the physician always remaining in control. This isn’t about replacing expertise – it’s about amplifying it,” added Dr. Atul Gupta. “By embedding AI into the procedure, DeviceGuide gives physicians an extra pair of eyes, effectively bionic vision, helping them treat more patients safely and confidently.”
Collaboration with Edwards Lifesciences
This innovation was developed in close collaboration with Edwards Lifesciences, the manufacturer of these repair devices. The solution combines Philips’ expertise in medical imaging and AI technologies with Edwards’ global leadership in structural heart innovation. Together, the companies have reimagined key parts of the mitral TEER procedural workflow.
“DeviceGuide demonstrates the impact of combining leading imaging and therapy expertise to develop solutions designed around the procedural workflow, a model that will shape the future of AI-enabled image-guided structural interventions,” said Mark Stoffels, Business Leader, Image Guided Therapy Systems.
This solution illustrates how Philips’ imaging and AI expertise can merge with the insights of leading therapy companies to innovate procedural workflows. This kind of collaboration is a model for developing the next generation of AI-enabled, image-guided innovations, centered on the needs of clinicians and their patients.
Read more on how Philips DeviceGuide works here.
[1] MDPI
Philips DeviceGuide enabled by EchoNavigator R5 is not available for sale or use in all countries. Its availability is subject to local regulatory clearance and market release. Please contact your Philips representative for details on product availability in your region.
*DeviceGuide is currently intended for use only with the Mitral TEER Therapy Device (Edwards PASCAL Ace).
**DeviceGuide assists physicians in visualizing and navigating the repair device within the heart. It supports, but does not perform, the therapeutic procedure itself.
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 61 05 58 16
E-mail: joost.maltha@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
FAQ
What did Philips announce on November 17, 2025 about DeviceGuide (PHG)?
How does DeviceGuide assist physicians during mitral valve repair (PHG)?
Is Philips DeviceGuide available worldwide for PHG shareholders to expect revenue from?
Which repair device is DeviceGuide currently intended to work with (PHG)?
Did Philips develop DeviceGuide alone or with a partner (PHG)?
When and where was DeviceGuide previewed related to Philips (PHG)?
